Dm medication abbreviation
Searched over 200M research papers
Summary
5 papers analyzed
These studies suggest "DM" is an abbreviation for Diabetes Mellitus.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Understanding DM Medication Abbreviation
Introduction to DM Abbreviation in Medical Context
The abbreviation "DM" is commonly used in medical literature to refer to "Diabetes Mellitus," a chronic metabolic disorder characterized by high blood sugar levels over a prolonged period. This abbreviation is widely recognized and utilized in various research studies and clinical discussions related to diabetes and its associated complications .
Drug Master File (DMF) and Abbreviated Dossiers
Overview of DMF in Taiwan
In Taiwan, the Drug Master File (DMF) is a critical database that records the quality of active pharmaceutical ingredients (APIs). Applications for DMFs can be submitted in two formats: full dossiers, which include complete technical information, and abbreviated dossiers, which contain partially complete technical information supplemented by an approved document from developed countries .
Advantages of Abbreviated Dossiers
Research indicates that abbreviated dossiers are more efficient in terms of regulatory approval. They tend to have higher acceptance rates and shorter review times compared to full dossiers. This efficiency is largely attributed to the use of Certification of Suitability to the Monographs of the European Pharmacopoeia (CEP), which is frequently employed in abbreviated applications . The policy of health authorities plays a significant role in streamlining the review process, making abbreviated dossiers a favorable option for pharmaceutical companies.
Diabetes Mellitus (DM) and Its Complications
Pathophysiology and Treatment of Type II DM
Diabetes Mellitus, particularly Type II DM, is a metabolic disorder resulting from decreased insulin activity and/or secretion. It is associated with various complications, including nephropathy, retinopathy, and cardiovascular issues. Treatment typically involves oral hypoglycemic agents such as insulin secretagogues, biguanides, insulin sensitizers, and SGLT2 inhibitors. For patients who do not achieve therapeutic goals with monotherapy, dual drug therapies are often recommended.
Impact of Cardiovascular Drugs on Glycemic Control
The management of patients with both DM and cardiovascular disease (CVD) requires careful selection of medications to avoid impairing glycemic control. Certain beta-blockers, renin-angiotensin-aldosterone system inhibitors, and select calcium channel blockers have been shown to have favorable glycometabolic profiles. This consideration is crucial for clinicians treating patients with concomitant DM and CVD to ensure both conditions are managed effectively without compromising glycemic control.
Conclusion
The abbreviation "DM" is widely used to denote Diabetes Mellitus in medical literature. In the context of drug master files, abbreviated dossiers offer significant advantages in terms of regulatory approval efficiency. For managing Type II DM, a combination of oral hypoglycemic agents and careful selection of cardiovascular drugs is essential to maintain optimal glycemic control and manage associated complications effectively.
Sources and full results
Most relevant research papers on this topic
